Skip to main content
. Author manuscript; available in PMC: 2016 Dec 23.
Published in final edited form as: N Engl J Med. 2016 Jun 23;374(25):2419–2429. doi: 10.1056/NEJMoa1510093

Table 1. Pretreatment Characteristics of Patients Included in the Analyses.*.

Characteristic Patients with Negative PET Findings Patients with Positive PET Findings Who Received BEACOPP (N = 172) All Eligible Patients (N = 1203)
ABVD (N = 470) AVD (N = 465)
Age at registration — yr
     Median 32 33 32 33
     Range 18–79 18–76 18–70 18–79
Age — no. (%)
     18–24 yr 121 (25.7) 117 (25.2) 47 (27.3) 299 (24.9)
     25–44 yr 231 (49.1) 223 (48.0) 75 (43.6) 576 (47.9)
     45–59 yr  80 (17.0)  81 (17.4) 32 (18.6) 213 (17.7)
     ≥60 yr 38 (8.1) 44 (9.5) 18 (10.5) 115 (9.6)
Male sex — no. (%) 261 (55.5) 252 (54.2) 92 (53.5) 656 (54.5)
ECOG performance status — no. (%)
     0 340 (72.3) 354 (76.1) 123 (71.5) 889 (73.9)
     1 113 (24.0) 96 (20.6) 40 (23.3) 271 (22.5)
     2 11 (2.3) 9 (1.9) 6 (3.5) 28 (2.3)
     3  6 (1.3) 6 (1.3) 2 (1.2) 14 (1.2)
     Missing 0 0 1 (0.6)   1 (0.1)
Ann Arbor stage — no. (%)
     II 195 (41.5) 197 (42.4) 73 (42.4) 500 (41.6)
     III 157 (33.4) 140 (30.1) 34 (19.8) 363 (30.2)
     IV 118 (25.1) 128 (27.5) 65 (37.8) 340 (28.3)
B symptoms — no. (%) 287 (61.1) 277 (59.6) 121 (70.3) 738 (61.3)
Bulky disease — no. (%) 133 (28.3) 150 (32.3) 79 (45.9) 386 (32.1)
International prognostic score — no. (%)§
     0 or 1 170 (36.2) 172 (37.0) 34 (19.8) 404 (33.6)
     2 or 3 219 (46.6) 224 (48.2) 84 (48.8) 579 (48.1)
     ≥4 75 (16.0) 67 (14.4) 52 (30.2) 209 (17.4)
     Missing 6 (1.3) 2 (0.4) 2 (1.2) 11 (0.9)
*

Positron-emission tomographic (PET) findings on the interim PET–computed tomographic (PET-CT) scan were scored with the use of a 5-point scale, according to the level of any residual uptake of 18F-fluorodeoxyglucose at involved sites on baseline PET and with higher scores indicating greater uptake. A score of 1, 2, or 3 was regarded as indicating negative findings, and a score of 4 or 5 was regarded as indicating positive findings. ABVD denotes doxorubicin, bleomycin, vinblastine, and dacarbazine, AVD doxorubicin, vinblastine, and dacarbazine, and BEACOPP bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone.

Values for the Eastern Cooperative Oncology Group (ECOG) performance status range from 0 to 5, with higher scores indicating greater disability.

Systemic B symptoms include weight loss, night sweats, and fever.

§

The international prognostic score ranges from 0 to 7, with higher scores indicating increased risk.